This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Denys-drash Syndrome
Information about Denys-drash Syndrome: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Denys-drash Syndrome
Most recent studies have shown that Denys-drash Syndrome shares some biological mechanisms with congenital-abnormality, depressive-disorder, diffuse-mesangial-sclerosis-(disorder), disorders-of-sex-development, edema, frasier-syndrome, kidney-diseases, kidney-failure, kidney-failure-chronic, kidney-neoplasm, leprosy, leprosy-lepromatous, malignant-neoplasms, neoplasms, nephroblastoma, nephrotic-syndrome, parkinson-disease, proteinuria-of-undiagnosed-cause, sclerosis.
Among the many pathways, these few ones have gauged particular interests from scientists studying Denys-drash Syndrome, and have been seen in publications frequently: Angiogenesis, Blood Circulation, Cell Adhesion, Cell Cycle, Cell Death, Cell Proliferation, Conjugation, Drug Resistance, Endocytosis, Excretion, Hypersensitivity, Immune Response, Kidney Development, Localization, Pathogenesis, Regeneration, Secretion, Tissue Regeneration, Translation, Transport
Quite a number of genes have been found to play important roles in Denys-drash Syndrome, such as ABCA4, AKR1C2, ALB, ATP2A2, DMD, GNA12, IL6, INS, MPZ, NPHS1, NR0B1, PAX6, PDC, PMP22, TNF, URI1, VEGFA, WT1. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.